KARYOPHARM THERAPEUTICS INC
KPTINASDAQTrading Snapshot
- Day Range
- $1.20 – $1.22
- 52-Week Range
- $1.20 – $10.99
- Volume
- $2.84B
- Avg Volume
- $2.77B
- Shares Outstanding
- 22.7M
- Next Earnings
- Dec 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $146M
- Last Q Revenue
- $33M
- P/E Ratio
- -0.1
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-7.77
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +117.1%
Why Investors Own KPTI
- ✓High-growth profile — revenue up +40.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KARYOPHARM THERAPEUTICS INC
KPTI
StockOtter · stockotter.spaceAbout KARYOPHARM THERAPEUTICS INC
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3